Veracyte Inc
NASDAQ:VCYT

Watchlist Manager
Veracyte Inc Logo
Veracyte Inc
NASDAQ:VCYT
Watchlist
Price: 42.84 USD 4.23% Market Closed
Market Cap: 3.3B USD
Have any thoughts about
Veracyte Inc?
Write Note

Veracyte Inc
Gross Profit

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Veracyte Inc
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
Veracyte Inc
NASDAQ:VCYT
Gross Profit
$291.1m
CAGR 3-Years
33%
CAGR 5-Years
29%
CAGR 10-Years
32%
Abbvie Inc
NYSE:ABBV
Gross Profit
$37.3B
CAGR 3-Years
0%
CAGR 5-Years
8%
CAGR 10-Years
9%
Gilead Sciences Inc
NASDAQ:GILD
Gross Profit
$22B
CAGR 3-Years
0%
CAGR 5-Years
4%
CAGR 10-Years
3%
Amgen Inc
NASDAQ:AMGN
Gross Profit
$19.7B
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
2%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Gross Profit
$9.2B
CAGR 3-Years
13%
CAGR 5-Years
24%
CAGR 10-Years
29%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Gross Profit
$12B
CAGR 3-Years
1%
CAGR 5-Years
15%
CAGR 10-Years
17%
No Stocks Found

Veracyte Inc
Glance View

Market Cap
3.3B USD
Industry
Biotechnology

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The company is headquartered in South San Francisco, California and currently employs 761 full-time employees. The company went IPO on 2013-10-30. The firm offers customized biomarker testing and analytical services. The company offers a complete range of in vitro diagnostic (IVD) and companion diagnostic development services to biopharmaceutical companies and diagnostic companies. The company offers tests across various diseases, which include Afirma Genomic Sequencing Classifier for thyroid cancer; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer; Prosigna Breast Cancer Assay for breast cancer; Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer; Envisia Genomic Classifier test for interstitial lung diseases; Decipher Bladder Genomic Classifier test for bladder cancer and Immunoscore Colon Cancer Test for colon cancer. The company also offers Immunogram, a spatial molecular analysis and bioinformatics tool that integrates genomic, transcriptomic and proteomic data to help researchers understand the intricacies of the tumor immune microenvironment.

VCYT Intrinsic Value
17.31 USD
Overvaluation 60%
Intrinsic Value
Price

See Also

What is Veracyte Inc's Gross Profit?
Gross Profit
291.1m USD

Based on the financial report for Sep 30, 2024, Veracyte Inc's Gross Profit amounts to 291.1m USD.

What is Veracyte Inc's Gross Profit growth rate?
Gross Profit CAGR 10Y
32%

Over the last year, the Gross Profit growth was 25%. The average annual Gross Profit growth rates for Veracyte Inc have been 33% over the past three years , 29% over the past five years , and 32% over the past ten years .

Back to Top